SeaStar Medical Shares Surge 52% on FDA Breakthrough Designation
By Colin Kellaher
SeaStar Medical Holding shares rose sharply on Wednesday after the medical-device company won a third Food and Drug Administration breakthrough-device designation for its Selective Cytopheretic Device.
Shares of the Denver-based company were recently changing hands at 69 cents, up 52%.
SeaStar said the latest designation covers the device for use with patients in a hospital intensive care unit with acute kidney injury and acute on chronic liver failure.
The FDA's breakthrough-devices program aims to expedite the development and review of technology that offers significant advantages over existing approved products.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 18, 2023 11:20 ET (15:20 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Markets Brief: Is It Really a Surprising Quarter for Earnings?
-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
After Earnings, Is Coke Stock a Buy, a Sell, or Fairly Valued?
-
Disney Earnings: Improved Streaming Results Come at the Expense of Continued Linear Weakness
-
Apple: We Expect New Models and New Chip to Spur Return to iPad Growth
-
Palantir Earnings: AI Platform Drives Strong Start to 2024
-
What I Hope My 14-Year-Old Learned at Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Amazon Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Dividend Stocks
-
3 Stocks With High Dividend Yields That Warren Buffett Likes